



Evaluation of the cell-mediated immune response to bovine respiratory syncytial virus infection in cattle
by Emery Wayne Field

A thesis submitted in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE
in Veterinary Science
Montana State University
© Copyright by Emery Wayne Field (1979)

Abstract:

Six Holstein calves were experimentally infected by intranasal instillation with 7.5×10^7 plaque forming units (PFU) of bovine respiratory syncytial virus (BRSV), strain VC-494. One calf was maintained as a noninfected control. The calves were evaluated for the development of a cell-mediated immune (CMI) response using the leukocyte migration inhibition (LMI) test under agarose and the delayed hypersensitivity skin test (DHST). Serological evaluations were conducted prior to infection and at the conclusion of the study using the indirect fluorescent antibody test (IFAT).

Results of the LMI test indicate that the infected calves did develop a CMI response which was detected as early as five days postinfection. The response, measured as migration inhibition, reached a maximum value of 34%, 21 days after the experimental infection. An enhanced inhibition, which developed more rapidly, was observed with leukocytes from one calf reinfected with BRSV.

DHS tests were conducted following the LMI evaluations. Infected calves developed intradermal reactions which reached maximal intensity between 48 and 72 hours. The control calf did not develop a delayed type of reaction. Results of the IFAT showed that serum antibody levels also increased in the calves following the experimental BRSV infection.

Results of this study indicated that both humoral and cell-mediated immune responses were elicited in the calves infected with BRSV, strain VC-494.

4

STATEMENT OF PERMISSION TO COPY

In presenting this thesis in partial fulfillment of the requirements for an advanced degree at Montana State University, I agree that the Library shall make it freely available for inspection. I further agree that permission for extensive copying of this thesis for scholarly purposes may be granted by my major professor, or, in his absence, by the Director of Libraries. It is understood that any copying or publication of this thesis for financial gain shall not be allowed without my written permission.

Signature Emery W. Field

Date August 22, 1979

EVALUATION OF THE CELL-MEDIATED IMMUNE RESPONSE
TO BOVINE RESPIRATORY SYNCYTIAL VIRUS
INFECTION IN CATTLE

by

EMERY WAINE FIELD

A thesis submitted in partial fulfillment
of the requirements for the degree


of


MASTER OF SCIENCE

in

Veterinary Science

Approved:


Chairman, Graduate Committee


Head, Major Department


Graduate Dean

MONTANA STATE UNIVERSITY
Bozeman, Montana

August, 1979

ACKNOWLEDGEMENTS

The author would like to extend his sincere appreciation to Dr. M. H. Smith for his support and encouragement throughout this study.

He would also like to thank his graduate committee for their contributions and advice with his research project. A special thanks go to Sandra Phillips and Donna Gollehon for their excellent technical assistance with this project.

Thanks also go to his wife Deanna and son Clint, for their patience and understanding during his study at Montana State University.

TABLE OF CONTENTS

LIST OF TABLES	v
LIST OF FIGURES	vi
CHAPTER	
1. INTRODUCTION	1
Statement of Purpose	2
2. LITERATURE REVIEW	4
Characteristics of the Virus	4
Human RSV	6
Bovine RSV	12
3. MATERIALS AND METHODS	29
Experimental Animals	29
Virus and Viral Antigen	29
Indirect Fluorescent Antibody Test	31
Delayed Hypersensitivity Skin Test	32
Leukocyte Migration Inhibition Test	34
4. RESULTS	37
Clinical Observations	37
Leukocyte Migration Inhibition Test	37
Delayed Hypersensitivity Skin Test	45
Indirect Fluorescent Antibody Test	46
5. DISCUSSION	48
6. SUMMARY	55

LIST OF TABLES

Table	Page
1. Maximum Postinfection Temperatures	37
2. LMI Test with BRSV Antigen	39
3. LMI Test with BRSV and IBR/PI-3 Antigen	45
4. Delayed Hypersensitivity Skin Test	46
5. Serological Response	47

LIST OF FIGURES

Figure	Page
1. LMI Migration Pattern	38
2. Mean LMI Response	40-41
3. LMI Response After Reinfection with BRSV	43-44

ABSTRACT

Six Holstein calves were experimentally infected by intranasal instillation with 7.5×10^7 plaque forming units (PFU) of bovine respiratory syncytial virus (BRSV), strain VC-494. One calf was maintained as a noninfected control. The calves were evaluated for the development of a cell-mediated immune (CMI) response using the leukocyte migration inhibition (LMI) test under agarose and the delayed hypersensitivity skin test (DHST). Serological evaluations were conducted prior to infection and at the conclusion of the study using the indirect fluorescent antibody test (IFAT).

Results of the LMI test indicate that the infected calves did develop a CMI response which was detected as early as five days post-infection. The response, measured as migration inhibition, reached a maximum value of 34%, 21 days after the experimental infection. An enhanced inhibition, which developed more rapidly, was observed with leukocytes from one calf reinfected with BRSV.

DHS tests were conducted following the LMI evaluations. Infected calves developed intradermal reactions which reached maximal intensity between 48 and 72 hours. The control calf did not develop a delayed type of reaction. Results of the IFAT showed that serum antibody levels also increased in the calves following the experimental BRSV infection.

Results of this study indicated that both humoral and cell-mediated immune responses were elicited in the calves infected with BRSV, strain VC-494.

CHAPTER 1

INTRODUCTION

Bovine respiratory disease (BRD) continues to constitute a major economic loss for cattle producers in the United States (71). The widespread use of vaccines against viral and bacterial pathogens currently associated with the disease has failed to prevent outbreaks of respiratory infection in cattle. This ineffectiveness of the vaccines suggests that other etiologic agents may be involved in the pathogenesis of the disease. The failure to prevent outbreaks of BRD also indicates that a complex interrelationship exists between environmental factors, the infectious agent, and the immune response of the host animal in determining the outcome of respiratory tract infection.

Bovine respiratory syncytial virus (BRSV) is widespread in cattle and is recognized as a primary etiologic agent of BRD (9, 94, 97, 104). Recent evidence suggests that the virus can also occur as a concurrent infection with other viral pathogens including parainfluenza-3 (PI-3), infectious bovine rhinotracheitis (IBR), and bovine viral diarrhea (BVD) viruses (9, 62). Vaccines have been developed against PI-3, IBR, and BVD viral infections but an effective vaccine against BRSV is unavailable.

The type of viral disease manifested and the severity, duration and distribution of the disease is in part a result of the inter-

action of the infectious agent and the host's defense mechanisms. These mechanisms are comprised of both specific and nonspecific factors. The nonspecific factors, usually active against a variety of viruses, constitute "native immunity", and are for the most part a genetic property of an animal species (89). The specific immune mechanisms, on the other hand, are dependent upon the host animal's exposure to a particular virus. There are two general types of effector mechanisms which mediate specifically acquired immunity; those mediated by cell products of sensitized lymphocytes (humoral immunity) and those mediated by the lymphocytes themselves and the cells recruited by these sensitized lymphocytes (cell-mediated immunity).

The humoral immune response of cattle to BRSV infection has been investigated using serological techniques (77). The relative importance of this response in counteracting the infection however, remains undefined. Cell-mediated immunity has not been demonstrated to participate in the immune response of cattle to BRSV infection. A better understanding of the importance of the immune response of cattle to BRSV infection will depend upon defining the mechanisms involved and how various events interphase to combat the infection.

Statement of Purpose

The purpose of this study was: (1) to determine if cell-

mediated immunity (CMI) is elicited following experimental infection of calves with BRSV and (2) if CMI is elicited, to determine the minimal time between exposure to the virus and detection of sensitized lymphocytes.

CHAPTER 2

LITERATURE REVIEW

Respiratory syncytial virus (RSV) is recognized as a respiratory tract pathogen in man and cattle. Since its initial isolation from a chimpanzee in 1956, the virus has been shown to be the major cause of severe respiratory disease in human infants (5, 16). The virus produces a type of infection and disease unlike that of any other known respiratory tract pathogen (14).

The first reported isolation of a bovine respiratory syncytial virus (BRSV) was in Switzerland in 1970 from cattle with acute respiratory disease (86). The virus was subsequently shown to be associated with bovine respiratory disease in several countries and is now recognized as one of the primary etiologic agents of the bovine respiratory disease complex (43).

Characteristics of the Virus

The human and bovine respiratory syncytial (RS) viruses together with the pneumonia virus of mice (PVM) are classified as pneumoviruses, members of the paramyxoviridae family (72, 111). Spherical forms of both the human and bovine RS viruses range from 80 to 400 nm in diameter (6, 48, 49, 54, 84). Filamentous forms, exceeding 2 μ m in length, have been observed budding from cytoplasmic membranes (84). Although there is still some controversy concerning the dimensions of the RSV helical nucleocapsid, it appears to be approximately 14 nm

in diameter with a helical pitch of 6.5 nm (6, 54). Virus assembly occurs by budding through virus modified cell membranes where the virion acquires its envelope containing glycoprotein surface projections (6, 49, 84). The lack of inhibition by halogenated deoxyribosides suggests that the viral genome consists of a single stranded RNA (39, 48).

Buoyant densities for both the human and bovine RS viruses have been determined and range from 1.22 to 1.24 g/ml (21, 48). Sensitivity to low pH has been demonstrated with complete loss of activity at pH 3.0 (39, 48, 86, 104). The virus also appears to be relatively thermostable, losing 90% of its infectivity when maintained at 55 C for 5 minutes (38, 48).

Unlike other members of the paramyxoviridae family, neither hemagglutination nor neuraminidase activity have been demonstrated with either virus (90). Strains of the virus are not serologically identical but antigenic variation is limited and does not appear to be progressive (20, 22).

The RS viruses can be grown in cell culture using conventional tissue culture techniques. Human RS virus has been grown in human cancer cells including HeLa, Hep 2, and Chang liver cells (55). The bovine RS virus replicates in a variety of bovine cells including kidney, lung, testicle, aorta, and rectum cells (86, 66, 104).

In cell culture, the primary cytopathic effect is the forma-

tion of multinucleated epithelial giant cells termed syncytia. These syncytia, developing within 5 to 6 days postinfection, often contain numerous eosinophilic cytoplasmic inclusion bodies (55, 86, 104).

Human RSV

In 1956, Morris and associates (81) isolated an agent from a chimpanzee with an upper respiratory tract infection. This newly discovered agent, an RNA virus, was shown to be serologically distinct from previously identified paramyxoviruses and was designated chimpanzee coryza agent (CCA). An etiologic association was established between this isolate and a respiratory illness observed in a laboratory worker who had been in close contact with the chimpanzee. In the following year Chanock and co-workers, attempting to recover new agents from infants with severe lower respiratory tract illness, reported two isolations of a similar virus from children in Baltimore (18). Using neutralization tests, the virus was shown to be serologically indistinguishable from the CCA. Cell cultures infected with the virus developed a syncytial type of cytopathic effect. Owing to its association with respiratory illness and the fact that it induced the formation of syncytia in cell culture, the virus was designated respiratory syncytial virus (RSV).

Serological surveys have shown that RSV infections are quite common in the human population. Over 70% of the persons tested possessed neutralizing antibodies for the virus by five years of age and

over 90% by 15 years of age (12, 15, 37). The lowest incidence of neutralizing antibody was found in the 6-month to one-year age group which is temporally associated with the disappearance of passively acquired maternal antibody.

Annual epidemics of RSV infections occur primarily from late fall to early spring, with the peak months being January and February. These epidemics are associated with a dramatic increase in the number of infants and young children requiring hospitalization for lower respiratory tract disease (15, 57). This is in contrast to the virtual absence of confirmed RSV infections during the summer months, May through August.

Since its initial isolation, RSV has emerged as the major respiratory tract pathogen of infancy and early childhood (5, 10, 16, 25, 110). The virus is also considered to be a major cause of fatal respiratory tract disease in the first year of life. A study in Britain has shown that 19 of 22 children with fatal respiratory tract infections were under one year of age and RSV was isolated from eight of these patients postmortem (34).

A variety of clinical patterns of respiratory illness have been associated with the isolation of RSV but the most common are bronchiolitis and bronchopneumonia (15). The virus was shown to be associated with respiratory illness in a large proportion of infants admitted to a children's hospital during the first three months of 1962.

The RSV illnesses ranged from mild upper respiratory tract infection to severe bronchiolitis and bronchopneumonia. A ten month old boy, from whom RSV was isolated, died 24 hours after admission to the hospital with severe lower respiratory tract disease. Microscopic examination of respiratory tissues revealed cellular necrosis of the tracheobronchial mucosa, focal consolidation of both lungs, and severe emphysema, suggesting an incomplete bronchial or bronchiolar obstruction (45).

The severe disease occurs most often in children one month to six months of age, the frequency of disease then decreases with increasing age (16, 17). Older children and adults usually develop a less severe disease with predominately an upper respiratory involvement (52). This age-illness relationship of RSV disease is still not completely understood but investigators have advanced several theories.

Infants with the severe disease were found to possess moderate to high levels of maternally derived antibody specific for the virus (87). The decreasing levels of these passively acquired antibodies with increasing age appeared to correlate with the decreasing frequency of disease. This apparent correlation indicated that serum antibody did not provide effective protection against the lower respiratory tract disease. Furthermore, these observations provided the basis for Chanock et al. (13) to speculate that serum antibody might actually

contribute to the development of the serious lung damage. They proposed that a type 2 or possibly a type 3 immune hypersensitivity reaction might result from the interaction of pre-existing antibody and viral antigen in the lungs.

Vaccination studies using a formalin-inactivated, alum-precipitated RSV vaccine appeared to provide support for this theory (56, 58). Children receiving this killed vaccine developed substantial levels of serum neutralizing antibody to the virus. Upon exposure to a wild-type RSV however, 80% of the children in the vaccinated group required hospitalization and two of the children died. This unexpected result was interpreted as clearly establishing the involvement of serum antibody in the pathogenesis of the severe RSV disease (13). Recent reports have failed to support this theory and it now appears that serum antibody does provide a protective effect against the severe disease (8, 61). Data from a 10-year study of respiratory illness in normal children indicate that gradually accumulating levels of humoral antibody parallel the acquired resistance to RSV infections (40). There is substantial reduction in the attack rate in susceptible individuals and also in the severity of illness produced by a third re-infection with RSV. These findings indicate that both age and immunity, although not necessarily serum antibody, act to ameliorate the illness associated with infection due to RSV.

If serum antibody does not provide adequate protection against the severe RSV disease, other mechanisms must be involved since older children and adults do show some resistance. Cell-mediated immunity (CMI) could conceivably play a significant role in limiting the cell to cell spread of the viral infection. Results obtained from vaccination trials and natural RSV infections indicate that a CMI response does occur but that it does not prevent the development of the serious disease (59, 98, 99).

The role of interferon in recovery from RSV infection is still unclear. Conflicting results have been obtained regarding the induction of interferon by RSV and its sensitivity to the antiviral protein (33, 41, 75). Although infants appear to be capable of producing significant levels of interferon, McIntosh (67) detected only low levels in children with RSV infections. Hall et al. (36) found that the quantity of interferon produced by children with RSV infections was significantly less than those with influenza and parainfluenza virus infections. Whether these results suggest that interferon is not involved in recovery from RSV infection or that low levels are adequate in limiting infection will require further investigation.

Local secretory antibody has been shown to be a major determinant in resistance to viral respiratory tract infections. Mills et al. (74) observed that high levels of specific IgA in nasal secretions prevented RSV infection in adult volunteers regardless of the

level of serum antibody. Other studies have indicated that local secretory antibody may also provide a curative effect in RSV infections. McIntosh et al. (68) found that the disappearance of virus from nasal secretions correlated with the appearance of secretory antibody. Nasopharyngeal epithelial cells from infants with confirmed RSV infections have been shown to be coated with an anti-RSV IgA (32, 69). This coating of the infected cell with specific antibody could neutralize viral particles as they bud from the surface of the infected cell. Another possibility is that the antibody prevents the successful maturation of virus at the cell surface, thereby preventing the release of infective viral progeny. This type of action has been demonstrated in influenza A infections where the antibody prevented the release of infective viral particles (24).

These studies coupled with the ineffectiveness of vaccine-induced serum antibody, have encouraged the development of an attenuated strain of RSV which can induce resistance without producing significant illness (11). A chemical mutagen, 5-fluorouridine, has been used to produce a temperature-sensitive (ts) mutant which is designated ts-1. When administered into the nasopharynx of adult volunteers, the mutant induced resistance without producing significant illness. It appeared genetically stable under laboratory conditions but when children were infected experimentally with the ts-1 they shed a genetically altered virus with a wild-type temperature

sensitivity (42). Current research efforts are directed at producing a more genetically stable ts mutant of the RSV. It will hopefully provide a means of preventing the severe disease which occurs in infants less than one year of age.

Bovine RSV

In 1968, Doggett et al. (23) found neutralizing activity to human RSV in bovine sera suggesting the presence of an antigenically similar agent in cattle. Then in 1970, Paccaud and Jacquier (86) reported the isolation of a viral agent from cattle in Switzerland. They isolated the virus from a cow and a calf during an outbreak of respiratory disease in February of 1967. The disease was characterized primarily by an upper respiratory tract infection with nasal discharge and a mild cough. In approximately one third of the cases however, a high fever developed with discrete signs of bronchopneumonia. The seroconversion of these cattle, in neutralization and complement-fixation tests, clearly established that the isolate was of bovine origin.

Neutralization tests using human sera indicated that the virus, or an antigenically related agent, was also present in the human population. This fact together with characteristics of the isolate such as acid-lability, chloroform sensitivity, and a syncytial type of cytopathic effect in cell culture, suggested that the virus might be a

bovine representative of the RSV. Cross-neutralization and complement fixation tests clearly established the close antigenic relationship between the isolate and human RSV. With this evidence the authors concluded that the new isolate was indeed a bovine respiratory syncytial virus (BRSV).

Following this initial isolation Inaba and associates (46, 47) reported the isolation of a BRSV from cattle during an outbreak of respiratory disease in Japan. The disease swept across Japan during the months from October 1968 to April 1969. Clinically ill cattle exhibited anorexia, depression, pyrexia, respiratory distress, and a mild cough. In fatal cases, emphysema and consolidation of the lungs were noted. The close antigenic relationship between this virus and human RSV was established using neutralization tests. Serological data indicated that the virus was widespread in Japan. Over 60% of the cattle tested possessed detectable levels of neutralizing antibodies to the virus. Experimental infection of a calf with the new isolate produced pyrexia, anorexia, depression, serous nasal discharge, and a leukopenia. The calf developed neutralizing antibody against the virus which were detectable two weeks postinoculation.

In 1971, Wellemans reported a BRSV isolate from cattle with respiratory disease in Belgium (112, 113). The virus was described as the principle viral etiologic agent associated with bovine respiratory disease in that country. Efforts were initiated to develop an

attenuated strain of BRSV which could be used in a vaccination program against the viral related disease.

Jacobs and Edington (50, 51) reported the isolation of a BRSV from a group of 14 calves in Dorset, England. The calves had a serous nasal discharge, pyrexia, increased respiration rate, and a mild cough. The isolation confirmed serological data that indicated the virus was prevalent throughout Britain. Experimental infection of gnotobiotic, colostrum-deprived, and conventional calves produced a temperature response with a serous nasal discharge in all three experimental groups. The virus was re-isolated from nasal secretions of infected calves four to ten days postinoculation.

The first isolation of BRSV in the United States was reported by Smith, Frey, and Dierks in 1974 (103). They isolated the virus from Iowa feedlot cattle with an acute respiratory disease. Biological and physical characteristics together with cross-neutralization tests indicated a close but non-identical relationship to human RSV (104). Serological data indicated that 81% of the cattle from 43 herds possessed serum antibody to the virus. Experimental infection of five calves with the isolate produced clinical illness characterized by anorexia, pyrexia, leukopenia, nasal discharge, and malaise. The virus appeared capable of producing illness in calves possessing maternal antibody for the virus.

Rosenquist, in 1974, reported the isolation of two strains of BRSV from nasal secretions of calves with acute respiratory disease in Missouri (94). The calves exhibited clinical signs of respiratory illness, including pyrexia, increased respiration rate, and nasal discharge. Three calves, out of a group of nine, developed significant levels of neutralizing antibody to the virus isolate.

Since its initial isolation in Iowa, the virus has been shown to be prevalent in several states. Potgieter and Aldridge (88), using the indirect fluorescent antibody test (IFAT) to detect BRSV specific antibody, reported that 73% of the cows from 160 herds in Oklahoma were seropositive for BRSV. In three herds in which respiratory disease developed, the incidence of BRSV seroconversion approached 100%. Mohanty et al. (76) conducted a serological survey of neutralizing antibody to BRSV in Maryland. Thirty-eight of 100 cattle surveyed possessed antibody to the virus. In a recent serological survey of Montana cattle at Montana State University, Smith (personal communication) demonstrated widespread exposure to the virus. These studies indicate that BRSV may be as prevalent in cattle as human RSV has been shown to be in the human population.

In the fall when calves are weaned, they are exposed to physical stress and are frequently placed in feedlots with calves from other geographical regions. These factors often contribute to the development of respiratory disease. The disease has been referred to

as "shipping fever" but new terminology designates the illness as "bovine respiratory disease complex". The present concept of the etiology of respiratory tract disease of cattle is that it is a multifactorial syndrome involving stress, viral, and bacterial infections (43). Parainfluenza-3 (PI-3), infectious bovine rhinotracheitis (IBR), and bovine viral diarrhea (BVD) viruses have been given considerable significance in the etiology of the disease but little attention has been given to the involvement of BRSV.

Lemkuhl and Gough (62) collected serum samples from early weaned Iowa fall calves shortly after the onset of respiratory tract disease. Seroconversion rate of cattle to IBR virus was 4.3%, PI-3 - 16.3%, BVD - 9.6%, and BRSV - 45.4%. They also observed an increased rate of seroconversion for IBR, PI-3, and BVD viruses in the presence of BRSV seroconversion. These results appear to implicate BRSV in this disease of calves with the possibility of BRSV infection facilitating infection by other viral pathogens.

In a recent report, Bryson and associates (9) described four outbreaks of calf pneumonia in which there was serological evidence of concurrent infections with PI-3 and BRS viruses. Calves exhibited reduced appetites, nasal discharge, coughing, dyspnea, and pyrexia. An emphysematous crackling was also noted over the diaphragmatic lobes of the lungs. Three calves out of a group of six failed to respond to antibiotic treatment and died within five days of the onset of disease.

Postmortem examination of these calves revealed pneumonia involving the cranial lobes and severe pulmonary emphysema. Purulent exudate was evident in the bronchioles and there were areas of intralobular hemorrhage. Microscopic examination revealed the most severe lesions were those in the bronchioles, respiratory acini, and small blood vessels. Bronchitis and bronchiolitis were evident, with affected airways containing an exudate of polymorphs, mononuclear cells, and desquamated epithelial cells. Alveolar lesions consisted of overinflated alveoli, areas of alveolar collapse, focal necrosis, alveolar edema, and congestion of the alveolar blood vessels. Multinucleated epithelial syncytia were prominent in bronchiolar and alveolar walls with intracytoplasmic inclusion bodies within these syncytia.

Whether BRSV was totally responsible for the lesions or acted in concert with PI-3 cannot be determined but the involvement of BRSV in the development of these lesions is most certainly implicated.

Immunological Response to BRSV Infection

Natural and experimental BRSV infections in cattle have been shown to elicit a humoral response with the development of detectable levels of both nasal secretory and serum antibody (47, 51, 77, 82, 94, 104, 113). The relative importance of these antibodies in the resistance to the viral infection, or recovery from it, has not been clearly established.

Serum antibody does not appear to play a prominent role in

resistance to viral respiratory tract infections. Mohanty et al. (77) observed that calves challenged intranasally with BRSV developed clinical illness in the presence or absence of circulating antibody. Smith et al. (104) also reported that calves with pre-existing serum antibodies for BRSV developed clinical illness upon intranasal challenge with the virus. Similar results have also been reported in studies with PI-3 virus infection of calves. Levels of serum antibody did not correlate with resistance to infection but did appear to be associated with reducing the severity of disease (27).

These studies in cattle are in agreement with the results of human RSV studies where the level of serum antibody failed to correlate with resistance to respiratory infection (13, 87). These studies also indicate that serum antibody appears to be involved in reducing the severity of respiratory illness.

Serum antibody plays a major role in preventing those diseases in which the virus must travel through the blood stream to reach its target organ. In respiratory tract infections where the target organ is also the portal of entry, local factors including interferon, secretory antibody, and local cell-mediated immunity appear to be the most important defense mechanisms (93).

A secretory antibody system has been identified in the bovine species with IgA being the predominant immunoglobulin in nasal and lacrimal secretions (64). This secretory antibody system can function

independently from the systemic antibody system and can be activated by local application of antigen (96, 109). This fact is of extreme importance where the primary site of virus replication is the respiratory tract. Studies of viral respiratory infection in man have shown that the presence of antibody in nasal secretions correlates with protection against influenza, parainfluenza, and RSV infections (1, 21, 65, 74, 95, 102).

Studies with PI-3 virus infection in cattle also indicate that local secretory antibody (IgA) confers better protection against respiratory tract infection than circulating antibody (27, 35). Mohanty et al. (77) reported that four of five calves inoculated intranasally with BRSV developed detectable levels of nasal secretory antibody. When these calves were re-challenged with the virus five weeks after the primary challenge, they were found to be solidly immune. This was interpreted as evidence of the importance of secretory antibody in resistance to BRSV infection. It should be noted however, that a non-specific factor, possibly interferon, may have been responsible for the observed immunity in these calves. These studies, while not clearly establishing secretory antibody as the protective mechanism in resistance to respiratory viral infection, strongly implicate the participation of antibody in the process.

In focusing our attention on these specifically acquired immune responses, i.e., the serum and secretory antibody responses, the

importance of nonspecific mechanisms of local protection should not be overlooked. Factors such as mucocilliary barriers, temperature, and nonspecific phagocytosis by alveolar macrophages play a significant role in resistance to viral infection. In addition, nonspecific effects of infection, such as cellular resistance due to interferon production, may often determine the final outcome of the disease (73).

Once a viral infection is established, with virus replication occurring in a fully susceptible host, active defense mechanisms must be elicited to combat the infection. As described earlier in this review, viruses that promote systemic infections with viremia are controlled primarily by circulating antibody. On the other hand, viruses which spread from cell to cell via intercellular bridges and which usually elaborate specific antigens on the cell surface, are more likely to elicit a CMI response (85, 115). Examples of this type of virus include members of the orthomyxo- and paramyxoviridae families. Most of the members of these families have been shown to elicit both cell-mediated and humoral immune responses (28).

The CMI response can occur locally in the respiratory tract after intranasal infection without a generalized response, or at least with a diminished one (78, 112). T-lymphocytes, stimulated by contact with viral antigen on the surface of infected cells, may become directly cytotoxic to the infected cells. These cytotoxic reactions are very likely to be important in the control of noncytolytic viral

infections (115). The interaction between these T-lymphocytes and the infected cells can also result in the release of soluble mediators called lymphokines. The biological activity of lymphokines affect the behavior of macrophages, polymorphonuclear leukocytes, lymphocytes, and other cell types in vitro. A list of these factors published in a report of a World Health Organization scientific group (115) is found in table 1.

The following is an excerpt from R.E. Rocklin's chapter on mediators of cellular immunity (29). It is a qualitative interpretation of the events that may occur in certain cell-mediated reactions based upon the existence of these lymphokines.

...." Antigen-sensitive lymphocytes, when stimulated by the appropriate antigen, become activated and start synthesizing the various lymphocyte mediators. Chemotactic factors for monocytes and polymorphonuclear leukocytes recruit inflammatory cells to the reaction site. Once there, the macrophages and polymorphonuclear leukocytes might be held at the site by MIF and LIF. Macrophages might be activated to an enhanced state by the action of the activating factor. Other lymphocytes are recruited to participate in the reaction by the mitogenic factor. Lymphocyte mitogenic factor nonspecifically activates the other lymphocytes in the area which would perhaps, in turn, start producing lymphocyte mediators. These events have the effect of amplifying an initially small reaction. Once activated, the inflammatory cells

Table 1. Biological activities of products of activated lymphocytes^a

A. Affecting macrophages

Migration inhibition factor	(MIF)	inhibits the migration of normal macrophages
Macrophage aggregation factor	(MAF)	agglutinates macrophages in suspension
Macrophage chemotactic factor	(MCF)	cause macrophages to migrate through micropore filter along gradient
Macrophage resistance factor (postulated)		renders macrophages non-specifically resistant to infection with certain bacteria and viruses
Cytophilic antibodies		confer on macrophages specific reactivity with antigen

B. Affecting lymphocytes

Blastogenic or mitogenic factor	(BF or MF)	induces blast cell transformation and tritiated thymidine incorporation in normal lymphocytes
Potentiating Factor	(PF)	augments or enhances on-going transformation in mixed lymphocyte culture or antigen-stimulated cultures
Cell cooperation or helper factor		produced by T cells, increases the number or rate of formation of Ab-producing cells <u>in vitro</u>
Suppressor factor (postulated)		inhibits activation of, and/or antibody production by B cells

Table 1. (Continued)

C. Affecting granulocytes

Inhibition factor	(LIF)	inhibits the migration of human buffy coat cells or peripheral blood leukocytes from capillary tubes or wells in agar plates
-------------------	-------	--

Chemotactic factor		causes granulocytes to migrate through micro-pore filter along a gradient
--------------------	--	---

D. Affecting cultured cells

Lymphotoxin	(LT)	cytotoxic for certain cultured cells, e.g., mouse L cells or HeLa cells
-------------	------	---

Proliferation inhibition factor and cloning inhibition factor	(PIF, CLIF)	inhibit proliferation of cultured cells without lysing them
---	-------------	---

Interferon		protects cells against virus infection
------------	--	--

E. Producing effects in vivo

Skin reactive factor (possibly a combination of several of the above activities)	(SRF)	in normal guinea pig skin induces indurated skin reactions that are similar histologically to delayed hypersensitivity reactions
--	-------	--

Macrophage disappearance factor		injected intraperitoneally, causes macrophages to adhere to peritoneal wall
---------------------------------	--	---

^aFrom: Cell-mediated immunity and resistance to infection. World Health Organization Technical Report Series No. 519. 1973. WHO, Geneva.

become bactericidal or tumoricidal. Furthermore, the vasoactive properties of some of the mediators may account for part of the inflammation. Other protein systems, including the complement system, the kinin system, and the clotting system are also called into play. If antigen remained at the site, such a reaction would continue, abating only as the antigen supply was exhausted."

This interpretation is purely speculative since it has not as yet been possible to confirm in vivo.

The apparent correlation between the interaction, in vitro, of sensitized lymphocytes and appropriate antigens, and delayed hypersensitivity skin reactions, led to the establishment of a series of in vitro correlates of cell-mediated immunity. These in vitro correlates have been extensively detailed and reviewed by Bloom and Glade (7), the World Health Organization (115), and McCluskey and Cohen (70). Therefore, consideration of this subject will be limited, with emphasis on the two techniques that relate directly to the experimentation described in this thesis.

Delayed Hypersensitivity Skin Test

When certain antigens are injected into the skin of sensitized animals, an inflammatory response may develop at the injection site. Erythema and swelling gradually appear, reaching maximal intensity from 24 to 72 hours after the injection. Histologically the reaction is

characterized by the accumulation of large numbers of macrophages and lymphocytes.

This response to the antigen can be transferred from sensitized to normal animals through the use of lymphocytes, but not by means of serum, indicating that the response is cell-mediated. The reaction is the result of the interaction of sensitized lymphocytes and appropriate antigen. These circulating, antigen-sensitive T-lymphocytes, upon encountering the injected antigen respond by both recruiting other lymphocytes and by dividing, differentiating, and releasing lymphokines. Some of these lymphokines, chemotactic factors and migration inhibition factors, are thought to be responsible for the accumulation of the large number of macrophages and lymphocytes. Vascular changes are mediated through the release of "skin-reactive factors" as well as by the release of lysosomal enzymes from the macrophages. As the macrophages ingest and eventually destroy the antigen, the stimulus for further lymphokine production diminishes, permitting the tissues to return to normal (108).

Skin testing with the appropriate antigen is the most important diagnostic test for CMI (115). Perhaps the best known example of this test is the Mantoux reaction, obtained by injecting tuberculin antigen into the skin of a sensitized animal. In cattle, the caudal fold is usually used as the injection site, with positive animals developing the characteristic erythema and indurated swelling

from 24 to 48 hours later. Although a neck site has been shown to be more sensitive the difficulty in restraining the animal make the caudal fold the most commonly used injection site in cattle. Other antigens including mumps, PI-3, histoplasmosis, and toxoplasmosis have been used for assessing delayed hypersensitivity to infectious diseases in man and animals (79, 115).

Leukocyte Migration Inhibition (LMI) Test

In 1967 Soborg and Bendixen (106) described an in vitro test based upon the inhibition of the migration of human peripheral leukocytes from glass capillary tubes. They found that this specific inhibition correlated with the presence of delayed hypersensitivity to brucella antigen. In recent years, this or modifications of the test, have been applied in a number of studies of cellular immunity. The method is now recognized as an in vitro correlate of cellular immunity in man and animals (105, 106).

In 1971 Clausen (19) developed a leukocyte migration inhibition (LMI) test in which the leukocytes migrate out from wells punched in an agarose gel. The leukocytes, primarily polymorphonuclear neutrophils (PMN), migrate out from the wells between the agarose and the surface of the petri dish, forming a circular area of migrated cells. The migration is inhibited if appropriate antigen is preincubated with the antigen-sensitive lymphocytes. These lymphocytes interact with the antigen and produce lymphokines, including a leukocyte inhibitory

factor (LIF). This LIF has been shown to be chemically distinct from the migration inhibitory factor (MIF) that inhibits the migration of macrophages in the macrophage migration inhibition test (91). The presence of cytophilic antibody, antigen-antibody complexes, and antigen alone do not affect the migration patterns in the LMI test (44).

Erard (26) demonstrated the suitability of the LMI test in agarose for routine detection of CMI in man. He found a good correlation between the PPD skin test and the inhibition of leukocyte migration using this antigen. Other investigators have employed the test to evaluate cellular immunity to numerous antigens including toxoplasmosis (31), hepatitis B (26), and candida antigen (4).

Anders and Natvig (71) used the LMI test to measure CMI to mumps, herpes simplex, adenovirus, and cytomegalovirus antigen. They found a good correlation between the results of the LMI test and skin reactivity to the antigen.

In 1977 Moreno-Lopez evaluated the CMI response of cattle to PI-3 virus infection. Test systems included the skin-hypersensitivity (SH) test, lymphocyte stimulation (LS) test, and the leukocyte migration inhibition (LMI) test. In four calves vaccinated intranasally with PI-3 virus, inhibition of leukocyte migration was observed two weeks after vaccination. Maximal inhibition reached 50 to 60% of control values, and occurred ten weeks postinfection. Results of the LMI test correlated with those obtained with both the

SH and LS tests. The LMI test was described as being more rapid to perform and more reproducible when compared to the LS test (80).

In a recent review of in vitro methods in CMI, the LMI test in agarose was characterized as being easy to perform, rapid, and a reliable correlate of cell-mediated immunity in man and animals (107). The test requires only a minimal amount of antigen which can be very crucial when only small amounts of purified antigen are available (26). The test offers an excellent tool in evaluating the cellular immune response to a large number of agents in both man and animals.

CHAPTER 3

MATERIALS AND METHODS

Experimental Animals

Seven Holstein calves, three to eight months of age, were purchased from local farms for use in this study. Two of the calves, approximately three months of age, were seronegative for BRSV. The remaining five calves possessed low levels of serum antibody for the virus as determined by the indirect fluorescent antibody test (IFAT) (88).

Six calves were inoculated intranasally with 7.5×10^7 plaque forming units (PFU) of BRSV/cell suspension. One of the calves was also inoculated intranasally with four milliliters of IBR/PI-3 modified live virus vaccine. The remaining calf was housed separately and was kept as a noninfected control.

Virus and Viral Antigen

Bovine RSV, strain VC-494, was propagated in a continuous cell line of Georgia bovine kidney (GBK) cells. Media for growth and maintenance of cell cultures consisted of Dulbecco's medium¹ supplemented with 10% fetal calf serum¹ (FCS) and adjusted to pH 7.4.

Infected cell cultures were incubated at 37 C for 72 - 96 hours and harvested when 70 - 80% of the monolayer showed a cytopathic

¹Grand Island Biological Co., Grand Island, New York.

effect (CPE). The cultures were then subjected to three cycles of freeze-thawing followed by sonication for 20 seconds at a setting of 35 kc/second.

Cellular debris was partially removed by low speed centrifugation (1000 X g) for 20 minutes. PFU titrations were then performed, the amount of virus present ranging from 1.5×10^6 to 5.0×10^6 PFU/ml. The viral suspension was aliquoted into appropriate amounts and frozen at - 70 C.

The BRSV test antigen was prepared from GBK cell cultures infected with strain VC-494. The infected cell cultures were frozen at - 70 C when 70 - 80% of the cell monolayer showed CPE. The virus/cell suspension was then allowed to thaw at 37 C and partially purified and concentrated according to the procedure described by Senterfit and Baldrige (100). Briefly, cell debris was partially removed by low speed centrifugation (1000 X g) for 20 minutes. The virus in the resulting supernatant fluid was then concentrated by precipitation with 6% (w/v) polyethylene glycol-6000¹ and partially purified by sucrose-gradient centrifugation for 16 hours at 105,000 X g. The resulting band of viral antigen was recovered and dialyzed against five changes of 50 volumes of phosphate-buffered saline solution (PBSS; pH 7.4) at 4 C. The concentration of viral protein was determined according to the method of Lowry et al. (63). A control antigen

¹Sigma Chemical Co., St. Louis, Missouri.

was prepared from noninfected cell cultures according to the procedure described above.

An IBR/PI-3 modified live virus vaccine¹ was used to inoculate one of the BRSV infected calves in this study. A dilution of this vaccine was also used as a test antigen in the LMI test.

Selection of Optimum Protein Concentration

The optimum protein concentration of the BRSV test antigen preparation was established by a dose-response study. A sample of the test antigen was adjusted to 10, 25, 50, 100, 150, 200, and 250 ug/ml of protein. The dilution of the antigen which inhibited sensitized leukocytes with minimal effect upon nonsensitized leukocytes was determined. The antigen preparation was diluted to a protein concentration of 50 ug/ml and stored at - 70 C in 0.1 ml aliquots until needed. The control antigen was treated similarly and stored until used in the LMI test.

Indirect Fluorescent Antibody Test (IFAT)

The IFAT was performed according to the procedure of Potgieter and Aldridge (88). Cells were grown in four-well chamber slides² and infected with BRSV, strain VC-494. After 20 hours of incubation, the

¹Jensen-Salsbery Lab., Kansas City, Missouri.

²Lab-Tek Products, Division Miles Lab. Inc., Kankakee, IL.

cells were washed with PBSS and fixed in acetone for ten minutes. The slides were stored at - 70 C until needed.

The test was performed by rehydrating the slides in a moist chamber at room temperature. Ten-fold dilutions of serum samples, including known negative and positive samples, were placed onto the infected cells. The slides were then incubated for 30 minutes at 37 C. Following three washings in PBSS (pH 7.5) the slides were air dried. An anti-bovine IgG conjugate ¹, diluted 1:16 in PBSS, was placed onto the slides and allowed to incubate for 30 minutes. This incubation was followed by three washings in PBSS, after which the slides were allowed to air dry. Coverslips were mounted using Wellcome's medium (pH 8.9).

The slides were examined using a microscope equipped with a darkfield condenser and a 200-W mercury vapor lamp. The intensity of the fluorescence was rated subjectively from 0 (negative) to a +4 (very intense).

Delayed Hypersensitivity Skin Test

Calves were injected intradermally into a shaved area on the lateral portion of the neck with 0.2 ml of the BRSV antigen and with 0.2 ml of the virus-free control antigen. The distance between the injection sites was approximately 10 cm. The thickness of the skin-fold at the site of each injection was measured using a micrometer

¹Miles Lab., Inc., Research division, Elkhart, In.

gauge shortly before and at 24, 48, and 72 hours after the injection of antigen. The injection sites were also checked at six to eight hours to insure that an Arthus type of reaction was not interfering with the latter evaluations.

Preparation of Peripheral Blood Leukocytes

Peripheral blood leukocytes were isolated using a modification of the method described by Naylor and Little (83). Blood (20 ml) was collected in a 20 cc syringe containing preservative free heparin¹ (10 IU/ml). The blood was divided equally into two centrifuge tubes, each containing 20 ml of distilled water. After shaking gently for 45 to 60 seconds, 10 ml of 0.0132 M phosphate buffer in 2.7% NaCl solution (pH 6.8) was added to restore isotonicity. The tubes were then centrifuged for ten minutes at 450 X g. The supernatant fluid was discarded and the pellets of white cells were washed once in Hank's BSS¹ containing heparin (5 IU/ml) followed by two washings in the same medium but without heparin. The cells were then resuspended in TC medium Parker 199¹ supplemented with 10% FCS, penicillin (60 IU/ml) and streptomycin (60 ug/ml)¹ to a concentration of 2 - 2.5 X 10⁸ cells per milliliter. The viability of the cells was found to be greater than 90% by trypan blue exclusion. Average differential count was 34% neutrophilic granulocytes, 56% lymphocytes, 7% monocytes, and

¹Grand Island Biological Co., Grand Island, New York.

3% eosinophilic granulocytes.

Preparation of Agar Medium for the LMI Test

The agarose plates were prepared using a modification of the procedure described by Gaines et al. (31). A 1.6% agarose suspension was mixed with FCS and TC medium Parker 199 supplemented with penicillin (60 IU/ml) and streptomycin (60 ug/ml). The final concentration was 0.8% agar and 10% FCS. Six milliliters of the agar medium was poured into disposable plastic petri dishes¹ (60 X 15 mm). The agar medium was allowed to cool at room temperature and was then placed in a cooler at 4 C for 15 to 30 minutes. Six wells, 3 mm in diameter, were punched in the agarose in each dish and the plugs were gently removed by suction. The dishes were then incubated at 37 C in an atmosphere of 2% CO₂ in air until use. The pH of the agarose medium was between 7.2 and 7.5 .

Leukocyte Migration Inhibition Test

A modification of the procedure described by Clausen (19) was used. The BRSV antigen was prepared as described above. Aliquots (0.2 ml) of the leukocyte suspension were incubated for 45 minutes at 37 C with aliquots (0.1 ml) of the BRSV test antigen and the control antigen. The cells were resuspended at ten minute intervals during

¹Lux Scientific Corporation, Newbury Park, California.

incubation to facilitate maximal contact with the antigen. Following this incubation period 10 ul of the mixture of cells and BRSV antigen or control antigen were placed into each well. Each dish contained three wells with cells and BRSV antigen and three wells with cells plus control antigen. The plates were incubated at 37 C in an atmosphere of 2% CO₂ in air enclosed within a moist chamber.

After 18 hours of incubation the cells were fixed in the agarose dish with 8.0% glutaraldehyde¹ for 30 minutes. The agar was then removed and the cells stained with crystal violet. The cells were rinsed twice with distilled water and then allowed to air dry.

The degree of cell migration was determined by measuring the linear distance of migration from the edge of the well to the perimeter of the area covered by the migrating cells. For this purpose a micrometer disc was used and the values expressed as the number of grids covered by migrating cells. The migration inhibition in percent was calculated for each test well according to the formula:

$$1 - \frac{\text{Mean linear migration of antigen treated cells}}{\text{Mean linear migration of control cells}} \times 100$$

An average of three replicates of each test was used in the final computations.

¹Sigma Chemical Co., St. Louis, Missouri.

Cytological Examination

Characterization of the migrated cells was accomplished by staining the cells after 18 to 20 hours of incubation. A coverslip (22 X 40 mm) was placed in the bottom of the plate before the addition of the agarose medium. The plate was then treated as previously described. At the end of the incubation period the plate was floated on water (45 C) for 15 minutes. The agarose medium was then carefully removed and the coverslip placed in absolute methanol at room temperature. The cells were stained in Wright's stain according to standard staining procedures.

CHAPTER 4

RESULTS

Clinical Observations

Calves experimentally infected with BRSV developed clinical illness characterized by nasal and lacrimal discharge, increased respiration rate, depression, and a transient pyrexia. Nasal discharge was first observed on the fifth day postinfection and persisted for four to five days. The maximum postinfection temperatures of individual calves are shown in table 1.

Table 1. Maximum Postinfection temperatures

Calf No.	Maximum temperature	Day Postinfection
1	104.6	8
2	105.6	8
3	107.2	8
4	104.8	9
5	102.8	8
6	105.6	8

Average preinfection temperatures ranged from 101.2 to 102.0 F.

Leukocyte Migration Inhibition Test

The migration of bovine peripheral leukocytes from wells punched in an agarose gel is shown in figure 1. The leukocytes migrated between the agarose layer and the surface of the dish to form a cir-




Figure 1. Cell migration patterns from wells containing leukocytes plus BRSV antigen (T), and from wells containing leukocytes plus virus-free control antigen (C).

cular area of cells. After 18 hours of incubation the migrating cells formed a clear-cut edge which facilitated accurate measurement.

Microscopic examination of the cells indicated that the polymorphonuclear (PMN) leukocytes were the predominant cells involved in the migration. Monocyte migration did not exceed 60% of the total linear migration. Lymphocytes were found only in close proximity to the wells.

Six of the calves were infected by intranasal instillation with 7.5×10^7 PFU of BRSV, strain VC-494. The remaining calf was kept as a noninfected control. The results of the LMI test are shown in table

2 and figure 2.

Table 2. LMI Test with BRSV Antigen*

Calf No.	Days Postinfection								
	-7	0	5	7	14	21	28	35	42
1**	4	5	11	20	34	39	32	27	29
2**	2	1	13	18	27	31	23	29	ND
3	8	14	28	27	34	35	32	32	26
4	11	13	23	36	30	37	37	31	25
5	8	6	27	33	32	30	32	29	30
6	14	13	22	31	30	33	30	27	27
7***	2	1	3	2	5	2	3	4	6

*Values expressed as percent migration inhibition.

**Seronegative at the beginning of the study.


***Control calf.

ND - Not Done

Calves number 1 and 2 were seronegative for BRSV antigen when the study began. Seven days postinfection leukocytes from these calves were inhibited from migrating in the presence of the viral antigen. Maximum inhibition values were observed on day 21 when the mean of inhibition values reached 35%.

Four calves, numbers 3 through 6, were seropositive for the virus prior to the experimental BRSV infection. Leukocytes from these

Figure 2. Mean LMI response of calves following experimental infection with BRSV. Results expressed as percent migration inhibition. Seropositive calves (□), Seronegative calves (□), Control calf (○).




calves were inhibited from migrating at the beginning of the LMI evaluation. Five days after exposure to the virus, leukocytes from these calves showed a significant increase ($p < 0.02$) in migration inhibition. The maximum inhibition values were observed 21 days postexposure when the mean of inhibition values approached 34%. Calf number 7 was kept as a noninfected control and its leukocytes did not show significant inhibition in the presence of the viral antigen.

The student's T test was employed to analyze the data. A significant difference ($p < 0.01$) in migration inhibition existed between the seronegative and seropositive calves before and at seven days after exposure to the virus. Differences in the migration inhibition of the two groups after seven days were not statistically significant. Migration inhibition of leukocytes from the six infected calves was significantly greater ($p < 0.002$) than that of the control calf.

Calf number 2 was reinfected with BRSV 85 days after the first experimental infection. No temperature response or clinical illness was observed. As shown in figure 3, migration inhibition (46%) was observed seven days after the reinfection with BRSV. Leukocytes from this calf were also tested against the IBR/PI-3 antigen. Inhibition of leukocyte migration was observed in wells containing BRSV antigen but not in wells containing the IBR/PI-3 antigen. The calf was then vaccinated by intranasal instillation with the IBR/PI-3 Nasalgen. The results of the LMI test on leukocytes from this calf after vaccination

Figure 3. LMI response of calf number 2 after two experimental infections with BRSV. Values expressed as percent migration inhibition. Calf number 2 (□), Control calf (○).



are shown in table 3.

Table 3. LMI Test with BRSV and IBR/PI-3 Antigens*

Calf No:***	Days Postinfection with IBR/PI-3 Nasalgen					
	0		7		14	
	BRSV	IBR/PI-3	BRSV	IBR/PI-3	BRSV	IBR/PI-3
2	43	4	ND**	20	31	36

*Values expressed as percent migration inhibition.

**ND - Not done.

***This calf was infected twice previously with the BRSV.

Delayed Hypersensitivity Skin Test

Results of the skin tests are shown in table 4. Calf number 6 developed an increase in skinfold thickness approximately 60 minutes after the intradermal injection of the BRSV antigen. The reaction diminished by 10 hours postinjection. All of the calves infected with BRSV had visible reactions at 24, 48, and 72 hours after antigen injection. In most of the calves maximum skinfold thickness occurred 48 hours after intradermal injection and were still present at 96 hours postinjection. Calf number 7 did not show a response to the test antigen at 48 or 72 hours but did develop a small increase (1.0 mm) in skinfold thickness at 24 hours postinjection. The results with the virus-free control antigen were uniformly negative and are not pre-

sented in the table.

Table 4. Delayed Hypersensitivity Skin Test with BRSV Antigen

Calf No.	Skin Reaction		Skinfold Thickness ^a	
	<u>1 hr.</u>	<u>48 hr.</u>	<u>1 hr.</u>	<u>48 hr.</u>
1	-	+	0.0	4.0
2	-	+	0.0	3.0
3	-	+	0.0	4.0
4	-	+	0.0	5.0
5	-	+	0.0	5.0
6	+	+	3.0	6.0
7*	-	-	0.0	0.0

^aIncrease in skinfold thickness in millimeters.

*Noninfected control calf.

Serological Response

The calves were tested for the presence of serum antibody using the IFAT as previously described. Table 5 shows that the calves infected with BRSV developed increasing levels of serum antibody specific for the BRSV.

Table 5. Serological Response to BRSV Infection

Calf No.	Preinfection	Postinfection
1	0	+3
2	0	3
3	+1	+4
4	+1	+4
5	+2	+4
6	+1	+3
7 (Control)	+1	+1

Rated subjectively from 0 (negative) to a +4 (very intense).

CHAPTER 5

DISCUSSION

Previous studies have assessed the immunological response of cattle to BRSV infection through the use of serological techniques. BRSV specific nasal secretory and serum antibodies are detected following both natural and experimental BRSV infections (76, 88, 104). The present study indicates that a cell-mediated immune response is also elicited following experimental intranasal BRSV infection of calves.

The LMI test under agarose is considered an in vitro correlate of CMI (26, 31, 71, 107). Using the direct technique, whereby antigen is incubated directly with the migrating peripheral leukocytes, presence of migration inhibition correlates well with the development of delayed cutaneous hypersensitivity reactions (2). This is interpreted as offering further support for the use of the LMI test as a reliable in vitro correlate of CMI. In the present study, using BRSV antigen, a good correlation was observed between the results of the LMI test and the development of delayed hypersensitivity skin reactions.

The six calves experimentally infected with BRSV developed a detectable in vitro response between five and seven days postinfection. The response, as measured by the LMI test using peripheral blood leukocytes, reached a peak between 7 and 21 days after calves were infected with the virus. The difference in migration inhibition of the sero-

negative calves versus the seropositive calves before and at seven days postinfection could relate to the latter having had prior exposure to the virus. Presumably they would possess an expanded population of sensitized lymphocytes specific for BRSV. This population of sensitized lymphocytes would be capable of mounting a response much earlier after viral infection. Leukocytes from two of the seropositive calves did develop maximum inhibition values by seven days postinfection. The other calves did not show maximum inhibition values until 21 days after infection with BRSV. The decrease in inhibition values observed in all of the calves by day 42 may reflect the decreased number of sensitized lymphocytes in the peripheral circulation.

One of the calves was reinfected with BRSV 85 days after the first experimental infection. As shown in figure 3, leukocytes from this calf developed a more pronounced migration inhibition (46%) which was detected by seven days postinfection. These results suggest a secondary or anamnestic type of response. Gadol et al. (30) have demonstrated that pulmonary as well as splenic T lymphocytes exhibit memory and are therefore capable of producing a secondary response. In their study, using the macrophage migration inhibition test, they detected a local anamnestic CMI response in the respiratory tract using both lung wash and splenic T lymphocytes. The response appeared earlier after challenge than the primary response but the intensity was not significantly greater. In the present study, the one calf rein-

ected with BRSV is not sufficient to definitely establish that a secondary response was elicited but this observation does offer evidence to support the need for future study in this area.

The mechanism of inhibition observed in the LMI test under agarose has been investigated and found to be related to a soluble product of activated lymphocytes. This biologically active mediator, a lymphokine, is designated leukocyte inhibitory factor (LIF) and has been shown to selectively inhibit the migration of polymorphonuclear (PMN) leukocytes (91, 92). Both T and B lymphocytes appear to be capable of producing lymphokines, but the weight of evidence continues to suggest that lymphokine production is predominantly a T cell function (53). The mechanism responsible for the inhibition observed in this study was not definitely established. Microscopic examination of the migrating cells did indicate that the PMN leukocyte was the principal cell involved in the migration and were the cells sensitive to the inhibition phenomenon.

Specificity of the LMI response was demonstrated using the IBR/PI-3 antigen. If the inhibition observed was the result of a non-specific response to foreign antigen, inhibition should also occur when the IBR/PI-3 antigen was used in the LMI test with lymphocytes sensitized to the BRSV antigen. As shown in table 3, no inhibition was detected in the presence of the IBR/PI-3 viral antigen prior to the intranasal challenge with the IBR/PI-3 Nasalgen.

At the conclusion of the LMI evaluations, the calves were tested for the presence of delayed hypersensitivity skin reactions. The experimentally infected calves developed intradermal reactions which reached maximal intensity between 48 and 72 hours after the injection of antigen. Although histological examination of these reactions was not performed, the time frame in which the reactions developed indicate that they were delayed hypersensitivity reactions. One animal developed an increase in skinfold thickness approximately 60 minutes after the intradermal injection of BRSV antigen. The early appearance of this reaction suggests that it was mediated by humoral antibodies, the most probable explanation being a type III or Arthus reaction. The animal did develop an indurated reaction that reached maximal intensity between 48 and 72 hours postinjection. The control calf did not show a response at 48 or 72 hours but did develop a small increase (1.0 mm) in skinfold thickness 24 hours after the antigen injection. The calf did possess a low titer of serum antibody to BRSV as determined by the IFAT. The increase in skinfold thickness may have been the result of an Arthus reaction.

The calves were also evaluated for a serological response to the experimental infection. Results from the IFAT indicate that the calves responded with a humoral response and developed increasing titers of serum antibody for BRSV. The control calf did not show an increase in serum antibody titer for BRSV during the test period.

The development of cell-mediated immunity to BRSV infection does not necessarily imply that this response contributes significantly to the resistance or recovery from the infection. The mode of virus replication and cell to cell spread appear to be important factors in determining the relative importance of cell-mediated and humoral responses in combating viral infections (115). Humoral immunity appears to be the predominant defense mechanism against those viruses that spread by an extracellular route. Specific antibody may coat the viral particles facilitating their ingestion by phagocytic cells or lysis of the viral particles may occur through the activation of the complement system. As a rule, viruses that bud from the surface membranes of infected cells or that cause the incorporation of virus-specified antigens in the infected cell's surface membrane are those that induce CMI. BRSV has been shown to bud from the surface of virus-modified membranes and to spread from cell to cell via intercellular bridges (60, 110).

In studying the CMI response to BRSV infection it is necessary to isolate it from as many other factors as possible. In doing this the illusion of separateness may be wrongly implied. Both humoral and cell-mediated immune responses are components of an overall defense mechanism and may often overlap one another. The recovery or resistance to a viral infection is probably dependent upon the finely tuned interaction of the various defense mechanisms comprising both specific and nonspecific factors.

Secretory antibody appears to function in providing resistance to BRSV infection in cattle (78). Recent studies, with human RSV, also indicate that high levels of secretory antibody may provide a curative effect and presumably this could hold true in cattle although work in this area is lacking (68). Serum antibody's involvement in defense against BRSV infection could occur once pulmonary inflammation developed. With this inflammation, an influx of inflammatory cells together with serum antibody might contribute in combating the infection (53). A cell-mediated immune response would appear to provide an effective mechanism by which infected cells could be lysed before release of infective virus. The CMI response could be mediated by the production of lymphokines, with the recruitment of alveolar macrophages and other cell types, or by the direct cytotoxic activity of sensitized T lymphocytes.

Presumably small numbers of specifically sensitized T lymphocytes, upon contact with appropriate antigen, produce sufficient quantities of lymphokines to effect changes in the host's defense mechanisms (115). The net result of this antigen-specific lymphokine production is the recruitment of nonsensitized lymphocytes, macrophages, and neutrophils. This recruitment of nonsensitized lymphocytes may act as an amplification system whereby these lymphocytes are induced to produce lymphokines that augment the initially small response to the viral infection (53).

Alveolar macrophages constitute the first line of defense in the lung. In addition to a crucial role in nonspecific cellular defense they also comprise key effector cells in CMI. Several of the lymphokines act specifically upon macrophages, resulting in the recruitment, activation, and trapping of these phagocytes at the reaction site. Macrophages, attracted to the site, appear capable of preventing viral spread by discouraging the formation of intercellular bridges (93). This response would appear to constitute a major mechanism for the defense of the bovine lung in limiting BRSV infection.

CHAPTER 6

SUMMARY

Results of the LMI test indicate that a CMI response was elicited following the intranasal infection with BRSV, strain VC-494. The response, as measured in migration inhibition, was detected as early as five days postinfection. The mean of inhibition values reached a maximum of 34%, 21 days after the calves were infected whereas the corresponding value before infection was 8.7%. An enhanced inhibition which developed more rapidly was observed with leukocytes from one calf reinfected with BRSV. This observation was suggestive of a secondary or anamnestic CMI response.

Delayed hypersensitivity skin tests were performed after the LMI evaluations were concluded. The six experimentally infected calves developed intradermal reactions which reached maximal intensity between 48 and 72 hours postinjection of the BRSV antigen, whereas the control calf gave negative results. Results of the IFAT showed that serum antibody levels also increased in the calves following infection.

Results of this study indicated that both humoral and cell-mediated immune responses were elicited following experimental infection of calves with the BRSV, strain VC-494.

LITERATURE CITED

1. Alford, R. H., R. D. Rossen, W. T. Butler, and J. A. Kasel. 1967. Neutralizing and hemagglutination-inhibition activity of nasal secretions following experimental human infection with A2 influenza virus. *J. Immunol.* 98: 724-731.
2. Anders, E. M., and J. B. Natvig. 1976. Cell-mediated immunity to viruses measured by the indirect agarose technique of leukocyte migration inhibition. *Cell. Immunol.* 27: 214-229.
3. Asso, J., and C. le Jan. 1978. Viral infections of the respiratory tract of calves: Local immunity. *Vet. Sci. Comm.* 1: 297-305.
4. Astor, S. H., L. E. Spitler, O. L. Frick, and H. H. Fudenberg. 1973. Human leukocyte migration inhibition in agarose using four antigens: Correlation with skin reactivity. *J. Immunol.* 110: 1174-1179.
5. Beem, M., F. H. Wright, D. Hamre, R. Egerer, and M. Oehme. 1960. Association of the chimpanzee coryza agent with acute respiratory disease in children. *N. Engl. J. Med.* 263: 523-530.
6. Berthiaume, L., J. Joncas, and V. Pavilanis. 1974. Comparative structure, morphogenesis, and biological characteristics of the respiratory syncytial (RS) virus and pneumonia virus of mice (PVM). *Arch. Ges. Virusforsch* 45: 39-51.

7. Bloom, B. R., and P. R. Glade. 1971. Conference on In Vitro Methods in Cell-Mediated Immunity. Academic Press, New York. 578 p.
8. Bruhn, F. W., and A. S. Yeager. 1977. Respiratory syncytial virus in early infancy: Circulating antibody and severity of infection. *Am. J. Dis. Child.* 131: 145-148.
9. Bryson, D. G., J. B. McFerran, H. J. Ball, and S. D. Neil. 1979. Observations on outbreaks of respiratory disease in calves associated with parainfluenza type 3 virus and respiratory syncytial virus infection. *Vet. Rec.* 104: 45-49.
10. Chanock, R. M. 1970. "Virological studies, epidemiology, and prophylaxis of virus infections in which respiratory manifestations predominate". Clinical Virology. W. B. Saunders Co., Phil.
11. Chanock, R. M. 1970. Prospects for control of acute viral and mycoplasmal respiratory tract disease by vaccination. *Science* 169: 248-256.
12. Chanock, R. M., and L. Finberg. 1957. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiological aspects of infection in infants and young children. *Am. J. Hyg.* 66: 291-300.

13. Chanock, R. M., A. Z. Kapikian, J. Mills, H. W. Kim, and R. H. Parrott. 1970. Influence of immunological factors in respiratory syncytial virus disease of the lower respiratory tract. *Arch. Environ. Health* 21: 347-355.
14. Chanock, R. M., H. W. Kim, C. Brandt, and R. H. Parrott. 1976. "Respiratory Syncytial Virus". In Viral Infections of Humans, Plenum Medical Book Co., New York. p. 365-382.
15. Chanock, R. M., H. W. Kim, A. J. Vargosko, A. Deleva, K. Johnson, C. Cumming, and R. H. Parrott. 1961. Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children. *J. Am. Med. Assoc.* 176: 647-653.
16. Chanock, R. M., and R. H. Parrott. 1965. Acute respiratory disease in infancy and childhood: Present understanding and prospects for prevention. *Pediatrics* 36: 21-39.
17. Chanock, R. M., R. H. Parrott, A. Z. Kapikian, et al. 1968. Possible role of immunologic factors in pathogenesis of RS lower respiratory tract disease. In Pollard M (ed): Perspectives in Virology. Academic Press Inc., New York p. 125-139.
18. Chanock, R. M., B. Roizman, and R. Meyers. 1957. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent. I. Isolation, properties, and characterization. *Am. J. Hyg.* 66: 281-290.

19. Clausen, J. E. 1971. Tuberculin-induced migration inhibition of human peripheral leukocytes in agarose medium. *Acta. Allergol.* 26: 56-80.
20. Coates, H. V., D. W. Alling, and R. M. Chanock. 1966. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. *Am. J. Epidemiol.* 83: 299-313.
21. Coates, H. V., B. R. Forsyth, and R. M. Chanock. 1966. Biophysical studies of respiratory syncytial virus. I. Density of respiratory syncytial virus and associated complement-fixing antigens in a Cesium and chloride density gradient. *J. Bact.* 91: 1263-1369.
22. Coates, H. V., L. Kendrick, and R. M. Chanock. 1963. Antigenic difference between two strains of respiratory syncytial virus. *Proc. Soc. Exp. Biol. Med.* 112: 958-964.
23. Doggett, J. E., D. Taylor-Robinson, and R. G. C. Gallop. 1968. A study of an inhibitor in bovine serum active against respiratory syncytial virus. *Arch. Ges. Virusforsch.* 23: 126-137.
24. Dowdle, W. R., J. C. Downie, and W. G. Laver. 1974. Inhibition of virus release by antibodies to surface antigens of influenza viruses. *J. Virol.* 13: 269-275.

25. Elliott, H. R., and U. Abdulla. 1978. Respiratory syncytial virus infection: admissions to hospital in industrial, urban, and rural areas. *Brit. Med. J.* 2: 796-798.
26. Erard, P. 1974. Technical study of the leukocyte migration inhibition test in agarose. *Clin. Exp. Immunol.* 18: 439-448.
27. Frank, G. H., and R. G. Marshall. 1971. Relationship of serum and nasal secretion neutralizing antibodies in protection of calves against Parainfluenza-3 virus. *Am. J. Vet. Res.* 32: 1707-1713.
28. Fudenberg, H. H., D. P. Stites, J. L. Caldwell, and J. V. Wells, editors. 1976. Basic and Clinical Immunology. Lange Medical Publications, California. p.182-194.
29. Fudenberg, H. H., D. P. Stites, J. L. Caldwell, and J. V. Wells, editors. 1976. Basic and Clinical Immunology. Lange Medical Publications, California. p. 102-113.
30. Gadoi, N., J. E. Johnson, and R. H. Waldman. 1974. Respiratory tract cell-mediated immunity: Comparison of primary and secondary response. *Inf. and Immun.* 9: 858-862.
31. Gaines, J. D., F. A. Araujo, J. L. Krahenbuhl, and J. S. Remington. 1972. Simplified in vitro method for measuring delayed hypersensitivity to latent intracellular infection in man (Toxoplasmosis). *J. Immunol.* 109: 179-182.

32. Gardner, P. S., and J. McQuillin. 1978. The coating of respiratory syncytial (RS) virus-infected cells in the respiratory tract by immunoglobulins. *J. Med. Virol.* 2: 165-173.
33. Gardner, P. S., R. McGuckin, A. J. Beale, and R. Fernandes. 1970. Interferon and respiratory syncytial virus. *Lancet.* 1: 574-575.
34. Gardner, P. S., D. C. Turk, W. A. Aherne, T. Bird, M. D., Holdaway, and S. D. M. Court. 1967. Deaths associated with respiratory tract infection in childhood. *Br. Med. J.* 4: 316-320.
35. Gutekunst, D. E., I. M. Paton, and F. J. Volenec. 1969. Parainfluenza-3 vaccine in cattle: Comparative efficiency of intranasal and intramuscular routes. *J. A. V. M. A.* 155: 1879-1885.
36. Hall, G. B., R. G. Douglas, R. L. Simons, and J. M. Geiman. 1978. Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. *J. Pediatrics.* 93: 28-32.
37. Hambling, M. H. 1964. A survey of antibodies to respiratory syncytial virus in the population. *Brit. Med. Journal.* 1: 1223-1225.

38. Hambling, M. H. 1964. Survival of respiratory syncytial virus during storage under various conditions. Brit. J. Exp. Pathol. 45: 647-655.
39. Hamparian, V. V., A. Hetler, and M. R. Hilliman. 1963. Contributions to characterization and classification of animal viruses. Proc. Soc. Exp. Biol. Med. 112: 1040-1049.
40. Henderson, S. W., A. M. Collier, W. A. Clyde, and F. W. Denny. 1979. Respiratory syncytial virus infections and immunity. N. Eng. J. Med. 300: 530-534.
41. Hill, D. A., S. Baron, and R. M. Chanock. 1969. Sensitivity of common respiratory viruses to an interferon inducer in human cells. Lancet 2: 187.
42. Hodes, D. S., H. W. Kim, R. H. Parrott, E. Camargo, and R. M. Chanock. 1974. Genetic alteration in a temperature sensitive mutant of respiratory syncytial virus after replication in vivo. Pro. Soc. Exp. Biol. Med. 145: 1158-1164.
43. Hoerlein, A. B. 1973. Preconditioning of beef cattle. J. Am. Vet. Med. Assoc. 163: 825-827.
44. Hoffman, P. M., L. E. Spitler, M. Hsu, and H. H. Fundenberg. 1975. Leukocyte migration inhibition in agarose. Cell. Immunol. 18: 21-30.

45. Hozel, A., L. Parker, W. H. Patterson, L. L. R. White, K. M. Thompson, and J. O. Tobin. 1963. The isolation of respiratory syncytial virus from children with acute respiratory disease. *Lancet*. 1: 295-298.
46. Inaba, Y., Y. Tanaka, K. Sato, H. Ito, T. Amori, and M. Matumoto. 1970. Nomi virus, a virus isolated from an apparently new epizootic respiratory disease of cattle. *Japan J. Microbiol.* 14: 246-248.
47. Inaba, Y., Y. Tanaka, K. Sato, T. Omori, and M. Matumoto. 1972. Bovine respiratory syncytial virus - studies on an outbreak in Japan, 1968 - 1969. *Japan J. Microbiol.* 16: 373-382.
48. Inaba, Y., Y. Tanaka, O. Tuneyoshi, and M. Matumoto. 1973. Physicochemical properties of bovine respiratory syncytial virus. *Japan J. Microbiol.* 17: 211-216.
49. Ito, Y., Y. Tanaka, Y. Inaba, and T. Omari. 1973. Structure of bovine respiratory syncytial virus. *Arch. ges Virusforsch* 40: 198-204.
50. Jacobs, J. W., and N. Edington. 1970. Respiratory syncytial virus in cattle. *Vet. Rec.* 87: 762.
51. Jacobs, J. W., and N. Edington. 1975. Experimental infection of calves with respiratory syncytial virus. *Res. Vet. Sci.* 18: 299-306.

52. Johnson, K. M., H. H. Bloom, M. A. Mufson, and R. M. Chanock. 1962. Natural reinfection of adults by respiratory syncytial virus. Possible relation to upper respiratory disease. *N. Engl. J. Med.* 267: 68-72.
53. Johnson, J. E., and J. R. Philip. 1977. The defense of the lung: Studies on the role of cell-mediated immunity. *Johns Hopkins Medical Journal* 141: 126-134.
54. Joncas, J. L., V. Berthiaume, and V. Pavilanis. 1969. The structure of the respiratory syncytial virus. *Virology* 38: 493-496.
55. Jordan, W. S., Jr. 1962. Growth characteristics of respiratory syncytial virus. *J. Immunol.* 88: 581-585.
56. Kapikian, A. Z., R. H. Mitchell, R. M. Chanock, A. Shuedoff, and C. E. Stewart. 1969. An epidemiological study of altered clinical reactivity to respiratory syncytial virus infection in children previously vaccinated with an inactivated RS virus vaccine. *Am. J. Epidemiology* 89: 405-421.
57. Kim, H. W., J. O. Arrobio, C. D. Brandt, B. C. Jeffries, G. Pyles, J. L. Reid, R. M. Chanock, and R. H. Parrott. 1973. Epidemiology of respiratory syncytial virus infection in Washington D. C. I. Importance of the virus in

different respiratory tract disease syndromes and temporal distribution of infection. Am. J. Epidemiology 98: 216-225.

58. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiology 89: 422-434.
59. Kim, H. W., S. L. Leiken, J. O. Arrobio, C. D. Brandt, R. M. Chanock, and R. H. Parrott. 1976. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediat. Res. 10: 75-78.
60. Knight, V. (Ed). 1973. Viral and Mycoplasmal Infections of the Respiratory Tract. Lea & Febiger, Philadelphia. 250 p.
61. Lamprecht, C. L., H. E. Krause, and M. A. Mufson. 1976. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J. Inf. Dis. 134: 211-217.
62. Lemkuhl, H. D., and P. M. Gough. 1977. Investigation of causative agents of bovine respiratory tract disease in a beef cow-calf herd with an early weaning program. Am. J. Vet. Res. 38: 1717-1720.

63. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with folin phenol reagent. *J. Biol. Chem.* 193: 265-275.
64. Mach, J. P., and J. J. Pahud. 1971. Secretory IgA, a major immunoglobulin in most bovine external secretions. *J. Immunol.* 106: 552-563.
65. Mann, J. J., R. H. Waldman, Y. Togo, G. C. Hainer, A. T. Dawkins, and J. A. Kasel. 1968. Antibody response in respiratory secretions of volunteers given live and dead influenza virus. *J. Immunol.* 100: 726-735.
66. Matumoto, M., Y. Inaba, H. Kuragi, K. Sato, T. Omori, Y. Goto, O. Hirose. 1974. Bovine respiratory syncytial virus: Host range in laboratory animals and cell cultures. *Arch. ges Virusforsch* 44: 280-290.
67. McIntosh, K. 1978. Interferon in nasal secretions from infants with viral respiratory tract infections. *J. Pediatrics* 93: 33-36.
68. McIntosh, K., H. B. Masters, I. Orr, R. K. Chao, and R. M. Barkin. 1978. The immunological response to infection with respiratory syncytial virus in infants. *J. Inf. Dis.* 138: 24-32.

69. McIntosh, K., J. McQuillin, and P. S. Gardner. 1979. Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection. *Inf. and Immun.* 23: 276-281.
70. McCluskey, R. T., and S. Cohen. 1974. Mechanisms of Cell-Mediated Immunity. John Wiley & Sons, New York.
71. McKercher, D. G. 1968. Bovine respiratory infections. *J. A. V. M. A.* 152: 729-737.
72. Melnick, J. L. 1976. Taxonomy of Viruses, 1976. *Prog. Med. Virol.* 22: 211-221.
73. Merigan, T. C. 1974. In conclusion reached at the IABS symposium on immunity to infections of the respiratory system in man and animals. London, April 22 - 25, *J. Biol. Stand.* 2: 343-352.
74. Mills, J., J. E. Van Kirk, P. F. Wright, and R. M. Chanock. 1971. Experimental respiratory syncytial virus infection of adults: Possible mechanisms of resistance to infection and illness. *J. Immunol.* 107: 123-130.
75. Moehring, J. M., and B. R. Forsyth. 1971. The role of the interferon and respiratory syncytial virus. *Lancet* 1: 584.
76. Mohanty, S. B., A. L. Ingling, and M. G. Lillie. 1975. Experimentally induced respiratory syncytial viral infection in calves. *Am. J. Vet. Res.* 36: 417-419.

77. Mohanty, S. B., M. G. Lillie, and A. L. Ingling. 1976.
Effect of serum and nasal neutralizing antibodies on
bovine respiratory syncytial virus infection in calves.
J. Inf. Dis. 134: 409-413.
78. Morag, A., K. R. Beutner, B. Morag, and P. L. Ogra. 1974.
Development and characteristics of in vitro correlates of
cellular immunity to rubella virus in systemic and mucosal
sites in guinea pigs. J. Immunol. 113: 1703-1709.
79. Morein, B., and J. Moreno-Lopez. 1973. Skin hypersensitivity
to parainfluenza-3 virus in cattle. Zbl. Vet. Med. 20:
540-546.
80. Moreno-Lopez, J. 1977. Cell-mediated immunity to PI-3 virus
in cattle: Evaluation of in vivo and in vitro tests. Zbl.
Vet. Med. B. 24: 231-240.
81. Morris, A. J., R. E. Blount, and R. E. Savage. 1956. Re-
covery of cytopathogenic agent from chimpanzee with coryza.
Proc. Soc. Exp. Biol. Med. 92: 544-549.
82. Moteane, M., L. A. Babiuk, and B. Schiefer. 1978. Studies on
the occurrence and significance of bovine respiratory syn-
cytial virus in Saskatchewan. Can. J. Comp. Med. 42: 246-248.

83. Naylor, P. F., and T. W. A. Little. 1975. A simple method for isolating leukocytes from bovine blood and their separation into lymphocyte and granulocyte fractions. *Res. Vet. Sci.* 18: 336-337.
84. Norrby, E., H. Marusyh and C. Orvell. 1970. Morphogenesis of respiratory syncytial virus in a green monkey kidney cell line (Vero). *J. Virology* 6: 234-242.
85. Notkins, A. L. 1974. Immune mechanisms by which the spread of viral infections is stopped. *Cell Immunology* 11: 478-483.
86. Paccaud, M. F., and C. I. Jacquier. 1970. A respiratory syncytial virus of bovine origin. *Arch. Ges. Virusforsch.* 30: 327-342.
87. Parrott, R. H., H. W. Kim, J. O. Arrobio, D. S. Hodes, B. R. Murphy, C. D. Brandt, E. Camargo, and R. M. Chanock. 1973. Epidemiology of respiratory syncytial virus infection in Washington, D. C. II. Infection and disease with respect to age, immunologic status, race and sex. *Am. J. Epidemiol.* 98: 289-300.
88. Potgieter, L. N. D., and P. L. Aldridge. 1977. Use of the indirect fluorescent antibody test in the detection of bovine respiratory syncytial virus antibodies on bovine serum. *Am. J. Vet. Res.* 38: 1341-1343.

89. Raffel, S. 1961. Immunity. Appleton-Century-Crofts, New York.
90. Richman, A. V., R. A. Pedreira, and N. M. Tauraso. 1971. Attempts to demonstrate hemagglutination and hemadsorption by respiratory syncytial virus. Appl. Microbiol. 21: 1099-1100.
91. Rocklin, R. E. 1974. Products of activated lymphocytes: Leukocyte inhibitory factor (LIF) distinct from migration inhibitory fact (MIF). J. Immunol. 112: 1461-1466.
92. Rocklin, R. E. and A. S. Rosenthal. 1977. Evidence that human leukocyte inhibitory factor (LIF) is an esterase. J. Immunol. 119: 249-252.
93. Roitt, I. 1977. Essential Immunology, 3rd Ed. Blackwell Scientific Publications, London. p. 201-206.
94. Rosenquist, B. D. 1974. Isolation of respiratory syncytial virus from calves with acute respiratory disease. J. Inf. Dis. 130: 177-183.
95. Rossen, R. D., R. H. Alford, W. T. Butler, and W. F. Vannier. 1966. The separation and characterization of proteins intrinsic to nasal secretions. J. Immunol. 97: 369-378.
96. Rossen, R. D., R. H. Alford, J. A. Kosel and R. B. Couch. 1971. The secretory immune system: It's relationship to respiratory viral infection. Prog. Med. Virol. 13: 194-238.

97. Rossi, C. R. and G. K. Kiesel. 1974. Serological evidence for the association of bovine respiratory syncytial virus with respiratory tract disease in Alabama cattle. *Inf. and Imm.* 10: 293-298.
98. Scott, R., M. O. DeLandazuri, P. S. Gardner, and J. J. T. Owen. 1977. Human antibody dependent cell-mediated cytotoxicity against target cells infected with respiratory syncytial virus. *Clin. Exp. Immunol.* 28: 19-26.
99. Scott, R., A. Kaul, M. Scott, Y. Chiba, and P. O. Ogra. 1978. Development of in vitro correlates of cell-mediated immunity to respiratory syncytial virus infection in humans. *J. Inf. Dis.* 137: 810-817.
100. Senterfit, L. B., and P. B. Baldrige. 1974. Separation and concentration of respiratory syncytial virus (RSV) antigen. *J. Immunol. Meth.* 4: 349-357.
101. Shigeta, S., Y. Hinuma, T. Suto, and N. Ishida. 1968. The cell to cell infection of respiratory syncytial virus in HEp-2 monolayer cultures. *J. Gen. Virol.* 3: 129-131.
102. Smith, C. B., J. A. Bellanti, and R. M. Chanock. 1967. Immunoglobulins in serum and nasal secretions following infection with type 1 parainfluenza virus and injection of inactivated vaccines. *J. Immunol.* 99: 133-141.

103. Smith, M. H., M. L. Frey, and R. E. Dierks. 1974. Isolation and characterization of a bovine respiratory syncytial virus. *Vet. Res.* 94: 599.
104. Smith, M. H., M. L. Frey, and R. E. Dierks. 1975. Isolation, characterization and pathogenicity studies of a bovine respiratory syncytial virus. *Arch. Vir.* 47: 237-247.
105. Soberg, M. 1967. In vitro detection of cellular hypersensitivity. *Acta Med. Scand.* 183: 167-174.
106. Soberg, M., and G. Bendixen. 1967. Human lymphocyte migration as a parameter of hypersensitivity. *Acta Med. Scand.* 181: 247-251.
107. Spitler, L. E., and C. V. Muller. 1976. "Leukocyte Migration Inhibition in Agarose". In Vitro Methods in Cell-Mediated and Tumor Immunity. Barry R. Bloom and J. R. David, eds. Academic Press, New York. 748 p.
108. Tisard, I. R. 1977. Veterinary Immunology. W. B. Saunders, Co., Philadelphia.
109. Todd, J. D. 1973. Immune response to parenteral and intranasal vaccination. *J. A. V. M. A.* 163: 807-809.
110. Tyrrell, D. A. J. 1975. A collaboration study of the aetiology of acute respiratory infections in Britain 1961 - 1964. *Brit. Med. J.* 2: 319-326.

111. Virus Subcommittee of International Nomenclature Committee.
Recommendation on virus nomenclature. *Virology* 21:
517-517.
112. Waldman, R. H., N. Gadol, P. F. Jurgensen, G. N. Olsen, and
J. E. Johnson, III. 1972. Secretary and systemic cell-
mediated and humoral immune response in humans and guinea
pigs to the inactivated influenza virus vaccine. *Adv.*
Exp. Med. Biol. 31: 87-95.
113. Wellemans, G., and J. Leunen. 1975. The respiratory syncytial
virus and the respiratory troubles of cattle. *Ann. Med.*
Vet. 119: 359-369.
114. Wellemans, G., J. Leunen, and E. Luchsinger. 1970. Respira-
tory ailments of cattle: Isolation of a virus (220/69)
with serologic resemblance to the human respiratory syncytial
virus. *Ann. Med. Vet.* 114: 89-93.
115. W. H. O. Technical Report Series No. 519. 1973. Cell-mediated
immunity and resistance to infection. Report of a W. H. O.
scientific group.

